Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib

Onkologie

Volumn 32, Issue 1-2, 2009, Pages 50-53

  Apostolidis, Leonidas ^a   Kahlert, Christoph ^b   Siegmund, Annika ^a   Thom, Rabea ^c   Horstmann, Solveig ^c   Jäger, Dirk ^a   Lordick, Florian ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Surgical University Hospital   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dermatomyositis; Hepatocellular carcinoma; Paraneoplastic syndromes of central nervous system; Sorafenib

Indexed keywords

AZATHIOPRINE; DEXPANTHENOL; PREDNISOLONE; SORAFENIB;

ADULT; ANAMNESIS; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; PARANEOPLASTIC SYNDROME; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZATHIOPRINE; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DERMATOMYOSITIS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; PREDNISOLONE; PYRIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 60249086679     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183750     Document Type: Article

References (35)

1. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the united states: an update. Ann Intern Med 2003;139:817-823.
3. Schurr R, Stölzel U, Schuppan D, Schwertner C, Steinberg J, Scherubl H: Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in Northeast Germany. Dtsch Med Wochenschr 2006;131:1649-1655.
4. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
5. Sigurgeirsson B, Lindelof B, Edhag O, Allander E: Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-367.
6. Voltz R, Graus F: Diagnosis and treatment of paraneoplastic neurological disorders. Onkologie 2004;27:253-258.
7. Abos J, Cervera R, Rozman M, Grau JM: Dermatomyositis and hepatic carcinoma. Med Clin (Barc) 1987;89:215-216.
8. Bernardini D, Arniaud D, Castellani P, Gauthier A, Mattei JP, Botta-Fridlund D: Association of dermatomyositis and hepatocellular carcinoma. One case one case. Gastroenterol Clin Biol 1998;22:104.
9. Biersack HJ, Rodermund OE, Winkler C: Scintigraphic findings of liver and spleen in dermatomyositis. Hautarzt 1976;27:498-500.
10. Cheng TI, Tsou MH, Yang PS, Sung SM, Chuang VP, Sung JL: Dermatomyositis and erythrocytosis associated with hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:1239-1240.
11. Gomez A, Solans R, Simeon CP, Selva A, Garcia F, Fonollosa V, Vilardell M: Dermatomyositis, hepatocarcinoma, and hepatitis C: comment on the article by Weidensaul et al.. Arthritis Rheum 1997;40:394-395.
12. Gray RG, Altman RD, Gottlieb NL: Aberrant serum enzyme patterns in dermatomyositis associated with hepatoma. J Rheumatol 1976;3:227-232.
13. Horie Y, Yamada M, Nakai K, Kawasaki H, Hirayama C, Matsui K, Kambe N, Shimao S: Combined hepatocellular-cholangiocarcinoma associated with dermatomyositis. J Gastroenterol Hepatol 1989;4:101-104.
14. Inuzuka M, Tomita K, Tokura Y, Takigawa M: Acquired ichthyosis associated with dermatomyositis in a patient with hepatocellular carcinoma. Br J Dermatol 2001;144:416-417.
15. Kee KM, Wang JH, Lee CM, Changchien CS, Eng HL: Chronic hepatitis C virus infection associated with dermatomyositis and hepatocellular carcinoma. Chang Gung Med J 2004;27:834-839.
16. Leaute-Labreze C, Perel Y, Taieb A: Childhood dermatomyositis associated with hepatocarcinoma. N Engl J Med 1995;333:1083.
17. Toshikuni N, Torigoe R, Mitsunaga M, Omoto A, Nakashima K: Dermatomyositis associated with hepatocellular carcinoma in an elderly female patient with hepatitis C virus-related liver cirrhosis. World J Gastroenterol 2006;12:1641-1644.
18. Wong KO: Dermatomyositis: A clinical investigation of twenty-three cases in Hong Kong. Br J Dermatol 1969;81:544-547.
19. Fiore G, Giacovazzo F, Giacovazzo M: HCV and dermatomyositis: Report of 5 cases of dermatomyositis in patients with HCV infection. Riv Eur Sci Med Farmacol 1996;18:197-201.
20. Germany RE, Cohen SM: Hepatitis C, collagenous colitis, and dermatomyositis occurring in the same patient. Am J Gastroenterol 2002;97:1848-1849.
21. Moccia F: Autoimmune thrombocytopenic purpura and dermatomyositis associated with chronic hepatitis C. A therapeutic dilemma. Ann Ital Med Int 1998;13:240-243.
22. Nakamura K, Matsumori A, Kusano KF, Banba K, Taniyama M, Nakamura Y, Morita H, Matsubara H, Yamanari H, Ohe T: Hepatitis C virus infection in a patient with dermatomyositis and left ventricular dysfunction. Jpn Circ J 2000;64:617-618.
23. Nishikai M, Miyairi M, Kosaka S: Dermatomyositis following infection with hepatitis C virus. J Rheumatol 1994;21:1584-1585.
24. Roux S, Seelig HP, Meyer O: Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol 1998;25:395-396.
25. Hammermann R, Warskulat U, Haussinger D: Anisoosmotic regulation of the mi-2 autoantigen mRNA in H4IIE rat hepatoma cells and primary hepatocytes. FEBS Lett 1998;435:21-24.
26. Strumberg D, Seeber S: Raf kinase inhibitors in oncology. Onkologie 2005;28:101-107.
27. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
28. Sturm JW, Keese M: Multimodal treatment of hepatocellular carcinoma (HCC). Onkologie 2004;27:294-303.
29. Grunwald V, Heinzer H, Fiedler W: Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007;30:519-524.
30. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-5620.
31. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H: Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 2007;35:1266-1271.
32. Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M: Three months treatment of active spondyloarthritis with imatinib mesylate: An open-label pilot study with six patients. Rheumatology (Oxford) 2006;45:1573-1575.
33. Magro F, Costa C: Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2006;12:1087-1089.
34. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y: Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002;147:406-407.
35. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH: Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-2642.